Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 8;10:66. doi: 10.3389/fphar.2019.00066

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Ercolano, De Cicco, Frecentese, Saccone, Corvino, Giordano, Magli, Fiorino, Severino, Calderone, Citi, Cirino and Ianaro.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Naproxen-HBTA inhibits metastatic features in a syngeneic melanoma model in vivo. Naproxen-HBTA (NAP-HBTA) (14 mg/kg, ), naproxen (10 mg/kg, ), or vehicle (CTR, ) were administered orally every day for 14 days. Tumor volume was monitored on the indicated days. The average of tumor volume and tumor weight with standard error is showed respectively in (A,B). In mice treated with NAP-HBTA tumor volume and tumor weight was significantly reduced (^∗∗∗P < 0.001 vs. CTR, n = 8; day 14) (A,B). CXCL1 plasma levels were significantly reduced in NAP-HBTA-treated mice (^∗∗P < 0.01 vs. CTR, n = 8; day 14) (C). Representative western blot analysis (D) and relative densitometry (E) of MMP-2 and MMP-13 proteins carried out on homogenate of subcutaneous melanoma excised from NAP-HBTA treated-mice or vehicle (CTR). In NAP-HBTA treated-mice the expression of both proteins was significantly reduced; GAPDH was detected as a loading control (^∗P < 0.05; ^∗∗P < 0.01 vs. CTR).

Inline graphic — Naproxen-HBTA inhibits metastatic features in a syngeneic melanoma model in vivo. Naproxen-HBTA (NAP-HBTA) (14 mg/kg, ), naproxen (10 mg/kg, ), or vehicle (CTR, ) were administered orally every day for 14 days. Tumor volume was monitored on the indicated days. The average of tumor volume and tumor weight with standard error is showed respectively in (A,B). In mice treated with NAP-HBTA tumor volume and tumor weight was significantly reduced (^∗∗∗P < 0.001 vs. CTR, n = 8; day 14) (A,B). CXCL1 plasma levels were significantly reduced in NAP-HBTA-treated mice (^∗∗P < 0.01 vs. CTR, n = 8; day 14) (C). Representative western blot analysis (D) and relative densitometry (E) of MMP-2 and MMP-13 proteins carried out on homogenate of subcutaneous melanoma excised from NAP-HBTA treated-mice or vehicle (CTR). In NAP-HBTA treated-mice the expression of both proteins was significantly reduced; GAPDH was detected as a loading control (^∗P < 0.05; ^∗∗P < 0.01 vs. CTR).